Loading data
MEDPNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.53 bn USD | 2.11 bn USD | 1.89 bn USD | 1.46 bn USD | 1.14 bn USD |
| Selling, general and administrative expense | 197.56 m USD | 180.18 m USD | 161.35 m USD | 131.4 m USD | 108.42 m USD |
| Operating profit | 534.94 m USD | 446.87 m USD | 336.83 m USD | 278.7 m USD | 198.62 m USD |
| Profit before tax | 542.38 m USD | 475.92 m USD | 335.68 m USD | 282.86 m USD | 201.85 m USD |
| Income tax expense | 91.25 m USD | 71.54 m USD | 52.87 m USD | 37.49 m USD | 20 m USD |
| Net income (reported basis) | 451.12 m USD | 404.39 m USD | 282.81 m USD | 245.37 m USD | 181.85 m USD |
| Net income attributable to common shareholders | 451.12 m USD | 404.34 m USD | 282.62 m USD | 245.21 m USD | 181.39 m USD |
| Basic earnings per share | 15.64 USD/share | 13.06 USD/share | 9.2 USD/share | 7.57 USD/share | 5.06 USD/share |
| Diluted earnings per share | 15.28 USD/share | 12.63 USD/share | 8.88 USD/share | 7.28 USD/share | 4.81 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.